Photo Credit: Courtesy, Sheba Hospital

Researchers have come up with a new treatment to fight metastatic melanoma – a fierce form of cancer that is particularly difficult to overcome. The new medication, called Keytruda, works on the body’s immune system and just received approval from the U.S. Food and Drug Administration (FDA).

Keytruda, produced by the Merck pharmaceutical firm in the United States, does not focus on destroying the cancerous tissue with chemicals, but rather initiates a different process in the body’s natural immune system, which then attacks the cancerous cells on its own.




The treatment mechanism is called “immunotherapy” and if it lives up to its expectations, the world of oncology could see a new revolution within just a few years. One of the clinical trials is being carried out at Tel Aviv’s Sheba Hospital at Tel Hashomer Medical Center.

Some 250 of newly diagnosed melanoma patients in Israel per year suffer from metastatic tumors. Malignant melanomas usually start on the skin but can also start elsewhere. Israel ranks among the 20 nations in the world with the highest morbidity rates for the disease, according to the International Agency for Research on Cancer.

“The new drug creates real potential for curing one of the deadliest forms of cancer at the negligible cost of light and tolerable side effects,” commented Prof. Jacob Schachter, head of the Ella Institute for Melanoma at Sheba Hospital. “Moreover, it completely alters the working assumptions in oncology treatment, as its working mechanism is effective in the war against other types of cancer too. There’s no doubt today that the holy grail of oncology lies in immunotherapy, which helps the body’s immune system to destroy the tumor’s cells itself.

“At this stage, we can only imagine the therapeutic potential of a combination of a number of such drugs, each acting on a different system, and some of which are already at an advanced stage of development. Among doctors, too, the scope of the breakthrough has yet to be digested.”